Alliance Company Profile: Bial

April 2018
21 pages
ID: 4544787

In this report:

Deal Information Deal Status Announced Date % Acquired Companies Information Acquirer Company Information Company Name Business Description

Also, Neurocrine will pay BIAL a percentage of net sales in exchange for the manufacture and supply of opicapone drug product.

This agreement enables Bial - Portela to strengthen its position in relevant therapeutic areas and expand its business in South Korea.

Summary

Table of Contents

Search Inside

Brief

Bial - Portela & Ca SA is a pharmaceutical company that discovers, develops and provides therapeutic solutions.The company affords products including anti-inflammatories, anti-diabetics, cardiovascular, anti-asthmatics, antibiotics, antidepressants and anti-anemics, among others.

Its products find its application in different therapeutic areas including antibiotic therapy, cardiovascular diseases, central nervous system, immunotherapy, musculoskeletal system, and respiratory disease.BIAL affords services including research, development, quality and innovation, serving health, scientific research, integrity rigor and high standards, universal values and organization, and administration of the RDI management system, among others.

The company has its presence in Angola, Cote d'Ivoire, Germany (DE), Italy (IT), Mozambique, Panama, Poland (PL), Spain (ES), Switzerland, and the UK. BIAL is based in Porto, Portugal (PT).

Bial - Portela & Ca SA - Pharmaceuticals & Healthcare - Transactions and Alliances Profile offers you detailled data and trend analysis of the company's Mergers and Acquisitions, alliances and financings.The study offers exhaustive data on Private Equity, Mergers and Acquisitions, Venture Financing, Equity/Debt Offerings, Venture Financing and Partnership transactions reported by the firm over a 5-year period.

The study provides extensive comparative data on: number of transactions, their values -subdivided into transactions types-, sub-sectors and areas.

GlobalData used data coming from Pharma eTrack deals database, primary and secondary research.

Overview

- Financial transactions - Analysis of the company's financial transactions including mergers and Acquisitions, Equity/Corporate debt offerings, Private equity investment, Venture capital financing and Alliances.

- Transactions by Year - Chart and table displaying information including the number of transactions and value described by the company by year, for a five year period.

- Transactions by Category - Chart and table depicting info containing the number of business deals and value announced by the company by type including Mergers and Acquisitions, Equity/Corporate debt offering etc.

- Transactions by Region - Chart and table presenting data on the number of accords and value described by the company by region, which comprises North America continent, Europe (EU), Asia Pacific (APAC), the Middle East (ME) and African continent and South and Central America.

- Transactions by Sub-sector - Chart and table showing data on the number of transactions and value announced by the company, by sub-sector.

- Main deals - Data on the company's main financial deals. Each such deal has a short statement, business deal type, deal justification; and deal financials and target company's main financial metrics and ratios.

- Business overview - A succinct description of the company's opertations.

- Main employees - A list of the main executives of the company.

- Significant locations and Subsidiaries - An inventory and contact details of main centers of operation and key partners (subsidiaries of the company).

- Main competitors - A list of the main competitors of the company.

- Main new developments - A succinct on latest news about the company.

Great reasons to purchase

Access comprehensive data on the company's financial transactions, company's expansion and divestiture and fund requirements

- The industry profile allows you to examine the company's financial transactions by region, by year, by industry segments and by category, for a five year period.

Gain knowledge on the growth and disinvestment strategy of the company

- The industry profile unveils transactions from the firm's core business segments' perspective to benefit you comprehend its business strategy.

Understand the main deals of the company with an overview of the recent financial transactions

- In-depth information on main recent deals includes a short statement of each deal, business deal type, deal motivation, financial deals and Target company's main financial metrics and ratios.

Get access to comprehensive data about the company's operations and detect potential clients and suppliers.

- The industry profile examines the corporate's business structure, areas and subsidiaries, main executives and key players.

Stay updated on main improvements affecting the firm

- Recent evolutions about the company exhibited in the profile advice you track main events.

Gain key aspects into the company for academic purposes or business purposes

- Highlight elements such as break up of transactions into types and info on detailed main deals are included into the industry profile to help your academic or business needs.

Note*: Some parts may be removed if info is not available for the company.

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 24h.

Our reports have been used by over 10K customers, including:

Get Industry Insights. Simply.

Latest reports & slideshows with insights from top research analysts
150+ Million searchable statistics with tables, figures & datasets
More than 25,000 trusted sources

Ahmad helps you find the right report:

+1 718 618 4302
Contact by email

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ

How we can help
- I am not sure if the report I am interested in will fulfill my needs. Can you help me?
- Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
- We buy reports often - can ReportLinker get me any benefits?
- Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
- I have had negative experiences with market research reports before. How can you avoid this from happening again?
- We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.
Report Delivery
- How and when I will receive my Report?
- Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
Payment conditions
- What payment methods do you accept?
- 1. Credit card : VISA, American Express, Mastercard, or
  2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
  3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
- What are ReportLinker’s Payment Terms?
- All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
- Are Taxes and duties included?
- All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
- I’m not satisfied. Can I be refunded?
- No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
User license
- The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

Purchase Reports From Reputable Market Research Publishers

PTC Therapeutics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

PTC Therapeutics, Inc.: Financial Highlights

$ 350
Company report
May 2018
by MarketLine

PTC Therapeutics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportSummaryMarketline’s PTC Therapeutics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances ...

Onxeo SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Onxeo SA: Financial Highlights

$ 350
Company report
May 2018
by MarketLine

Onxeo SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportSummaryMarketline’s Onxeo SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes ...

Myriad Genetics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Myriad Genetics, Inc.: Financial Highlights

$ 350
Company report
May 2018
by MarketLine

Myriad Genetics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportSummaryMarketline’s Myriad Genetics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and ...

Shanghai Fosun Pharmaceutical (Group) Co., ... $ 350 May 2018

ProMetic Life Sciences Inc.: Financial Hig ... $ 350 May 2018

Solvay Group: Financial Highlights $ 350 May 2018

Mitsubishi Tanabe Pharma Corporation: Fina ... $ 350 May 2018

ImmunoGen, Inc.: Financial Highlights $ 350 May 2018

Five Prime Therapeutics, Inc.: Financial H ... $ 350 May 2018

Bayer AG: Financial Highlights $ 350 May 2018

More Reports:

Pharmaceutical in Spain (299)

Pharmaceutical in the World (6535)

Pharmaceut... in the United States (3468)

Pharmaceutical in China (732)